Introduction
subfertility, miscarriages, Aneuploidy
ANEUPLOIDY, MISCARRIAGES, ANEUPLOIDIES, MISCARRIAGE, ANEUPLOIDY
Aneuploidy is common among preimplantation human embryos used in in vitro fertilization (IVF). Abnormal chromosome numbers can negatively affect the outcome of IVF such as implantation failure or miscarriage [Preimplantation genetic testing for aneuploidies (PGT-A) provides a robust alternative to avoid the selection of embryos with aneuploidy [Patients may perceive the use of PGT-A as an effective way of excluding abnormal embryos, thus helping to reduce unnecessary embryo transfers and decrease the cost [Of note, a largest randomized multicenter clinical study (CESE-PGS trial) of aneuploidy has discovered that the cumulative live birth rate (CLBR) for women between 20 and 37 year-old has not been effectively improved in China. Nevertheless, due to PGT-A, fewer embryo transfers were required, and fewer miscarriages occurred to achieve the same CLBR compared with the control group [Currently, subfertility patients are required to bear 100% of the costs of assisted reproductive treatments themselves in most areas of China. On February 21, 2022, the Beijing Health Insurance Bureau released a basic health insurance reimbursement policy for assisted reproductive technology, including 16 programs, and it would officially take effect on March 26, 2022 [Information on the cost-effectiveness of PGT-A for women undergoing IVF can help patients, clinicians, and health insurers in their decisions making process regarding to whether utilizing and paying for new technology or not. This study aimed to examine the cost-effectiveness of PGT‑A in women with a good prognosis from the Chinese healthcare system perspective.